Meta Health eyes 30% of Aios Bio Sciences share capital

It is part of Meta Health’s efforts to grow the group’s healthcare business

Meta Health Limited is eyeing to acquire 30% of the entire issued and paid-up share capital of Aios Bio Sciences from Davin Ng and other shareholders.

The transaction is part of Meta Health’s efforts to grow the group’s healthcare business and diversify its revenue streams by expanding into the complementary segment of the manufacturing and distribution of medical and surgical consumables.

Aios Bios is a private company limited by shares incorporated in Singapore on 25 July 2022.

Based on the information extracted from the Accounting and Corporate Regulatory Authority, Ng is a director of the company and holds 33.3% of the entire issued and paid share capital.

Reaching the people who run Asia's businesses is harder than it used to be.

Inboxes are crowded. Attention is short. The executives you most want to reach — the founders, CFOs, and operators who actually move budgets — are the hardest to find through the usual channels. If you're building a company, a category, or a reputation, you already know this.

We've spent twenty years building the room they read. Singapore Business Review is where senior decision makers in Singapore and across Southeast Asia come for business coverage they can't get elsewhere — in print, online, and in person at the summits and roundtables we host across seven markets.

If you have something these readers should know about — a point of view worth publishing, a product worth their attention, an event worth their time — we'd like to hear what you're trying to do.

Book a meeting

| Or download the media kit (PDF)

240,000 senior readers quarterly in print Top 1,700 Singapore companies reached

7 markets across Southeast Asia